Please Wait.....

Report

North America Breast Cancer Drugs Market - Industry Trends and Forecast to 2034

Market Report I 2023-10-01 I 179 Pages I Data Bridge Market Research

The North America breast cancer drugs market is expected to reach USD 21,400.33 million by 2030 from USD 10,238.79 million in 2022, growing at a CAGR of 9.8% during the forecast period of 2023 to 2030.
Market Segmentation
North America Breast Cancer Drugs Market, By Product Type (Medication, Chemotherapy, Targeted Therapy, Radiation Therapy, and Others), Cancer Type (Invasive Ductal Carcinoma (IDC), Invasive Lobular Carcinoma (ILC), Inflammatory Breast Cancer, Paget's Disease of the Nipple, Angiosarcoma of the Breast, Phyllodes Tumors of the Breast, Non-Invasive (In-situ) Types of Breast Cancer, Ductal Carcinoma In Situ (DCIS), Lobular Carcinoma In Situ (LCIS), Metastatic Breast Cancer, and Others), Stages (Stage 0, Stage I, Stage II, Stage III, and Stage IV), Drug Type (Generic and Branded), Age Group (Geriatric and Adults), Route of Administration (Oral and Intravenous), End User (Hospitals, Specialty Clinics, Cancer Centers, and Others), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, and Online Pharmacy), Country (U.S., Canada, and Mexico) - Industry Trends and Forecast to 2030

Overview of North America Breast Cancer Drugs Market Dynamics

Driver
- Advancement in drugs associated with breast cancer treatment

Restraint

- Rising cost of drugs associated with cancer treatment

Opportunity

- Government initiatives and other funding sources for cancer research
Market Players

Some of the major market players operating in the North America breast cancer drugs market are:

- F. Hoffmann-La Roche Ltd
- Pfizer Inc.
- AstraZeneca
- Novartis AG
- Eli Lilly and Company
- Merck & Co., Inc.
- Sanofi
- Bristol-Myers Squibb Company
- Eisai Co., Ltd.
- Mylan N.V. (A Subsidiary of Viatris Inc.)
- Teva Pharmaceutical Industries Ltd.
- Kyowa Kirin Co., Ltd.
- MacroGenics, Inc.
- Gilead Sciences, Inc.
- Takeda Pharmaceutical Company Limited
- AbbVie Inc.

TABLE OF CONTENTS
1 INTRODUCTION 16
1.1 OBJECTIVES OF THE STUDY 16
1.2 MARKET DEFINITION 16
1.3 OVERVIEW OF NORTH AMERICA BREAST CANCER DRUGS MARKET 16
1.4 CURRENCY AND PRICING 18
1.5 LIMITATIONS 18
1.6 MARKETS COVERED 18
2 MARKET SEGMENTATION 21
2.1 MARKETS COVERED 21
2.2 GEOGRAPHICAL SCOPE 22
2.3 YEARS CONSIDERED FOR THE STUDY 23
2.4 CURRENCY AND PRICING 23
2.5 DBMR TRIPOD DATA VALIDATION MODEL 24
2.6 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS 27
2.7 DBMR MARKET POSITION GRID 28
2.8 MULTIVARIATE MODELLING 29
2.9 PRODUCT TYPE LIFELINE CURVE 30
2.10 MARKET END USER COVERAGE GRID 31
2.11 SECONDARY SOURCES 32
2.12 ASSUMPTIONS 32
3 EXECUTIVE SUMMARY 33
4 PREMIUM INSIGHTS 36
4.1 PORTER'S FIVE FORCES 37
4.2 PESTEL ANALYSIS 38
4.3 EPIDEMIOLOGY 39
4.4 PIPELINE ANALYSIS 40
5 REGULATIONS 41
6 MARKET OVERVIEW 45
6.1 DRIVERS 47
6.1.1 ADVANCEMENT IN DRUGS ASSOCIATED WITH BREAST CANCER TREATMENT 47
6.1.2 INCREASING INCIDENCE OF BREAST CANCER ACROSS DIFFERENT COUNTRIES 48
6.1.3 INCREASING DEVELOPMENT IN THE FIELD OF TARGETED THERAPY FOR BREAST CANCER 48
6.1.4 INCREASING USAGE OF HORMONE THERAPY IN BREAST CANCER TREATMENT 49
6.1.5 GROWING NUMBER OF SCREENING PROGRAMS RELATED TO BREAST CANCER 50
6.2 RESTRAINTS 51
6.2.1 RISING COST OF DRUGS ASSOCIATED WITH CANCER TREATMENT 51
6.2.2 ADVERSE SIDE EFFECTS AND COMPATIBILITY CONCERNS 52
6.3 OPPORTUNITIES 53
6.3.1 GOVERNMENT INITIATIVES AND OTHER FUNDING SOURCES FOR CANCER RESEARCH 53
6.3.2 INTEGRATION OF ARTIFICIAL INTELLIGENCE (AI) IN DRUG DEVELOPMENT 54
6.3.3 USAGE OF ADJUVANT THERAPIES 55
6.4 CHALLENGES 56
6.4.1 COMPLICATIONS ASSOCIATED WITH CHEMOTHERAPY 56
6.4.2 LACK IN EARLY DETECTION OF BREAST CANCER 56
7 NORTH AMERICA BREAST CANCER DRUGS MARKET, BY PRODUCT TYPE 57
7.1 OVERVIEW 58
7.2 MEDICATION 60
7.2.1 ANASTROZOLE (ARIMIDEX) 61
7.2.2 CYCLOPHOSPHAMIDE (CYTOXAN) 61
7.2.3 EXEMESTANE (AROMASIN) 61
7.2.4 LETROZOLE (FEMARA) 61
7.2.5 OTHERS 61
7.3 CHEMOTHERAPY 61
7.3.1 FLUOROURACIL 62
7.3.2 METHOTREXATE 62
7.3.3 PACLITAXEL 62
7.3.4 EPIRUBICIN 62
7.3.5 DOCETAXEL 63
7.3.6 OTHERS 63
7.4 RADIATION THERAPY 63
7.5 TARGETED THERAPY 63
7.5.1 PEMBROLIZUMAB 64
7.5.2 OLAPARIB 64
7.5.3 LAPROTRECTINIB 64
7.5.4 ENTRECTINIB 64
7.5.5 OTHERS 64
7.6 OTHERS 65
8 NORTH AMERICA BREAST CANCER DRUGS MARKET, BY STAGES 66
8.1 OVERVIEW 67
8.2 STAGE I 70
8.3 STAGE II 70
8.4 STAGE 0 71
8.5 STAGE III 72
8.6 STAGE IV 72
9 NORTH AMERICA BREAST CANCER DRUGS MARKET, BY DRUG TYPE 73
9.1 OVERVIEW 74
9.2 BRANDED 76
9.3 GENERIC 77
10 NORTH AMERICA BREAST CANCER DRUGS MARKET, BY AGE GROUP 78
10.1 OVERVIEW 79
10.2 GERIATRIC 81
10.3 ADULTS 82
11 NORTH AMERICA BREAST CANCER DRUGS MARKET, BY CANCER TYPE 83
11.1 OVERVIEW 84
11.2 INVASIVE DUCTAL CARCINOMA (IDC) 87
11.3 INVASIVE LOBULAR CARCINOMA (ILC) 87
11.4 INFLAMMATORY BREAST CANCER 88
11.5 PAGET'S DISEASE OF THE NIPPLE 88
11.6 ANGIOSARCOMA OF THE BREAST 89
11.7 PHYLLODES TUMORS OF THE BREAST 89
11.8 NONINVASIVE (IN-SITU) TYPES OF BREAST CANCER 90
11.9 DUCTAL CARCINOMA IN SITU (DCIS) 90
11.10 LOBULAR CARCINOM AIN SITU (LCIS) 91
11.11 METASTATIC BREAST CANCER 91
11.12 OTHERS 92
12 NORTH AMERICA BREAST CANCER DRUGS MARKET, BY ROUTE OF ADMINISTRATION 93
12.1 OVERVIEW 94
12.2 INTRAVENOUS 97
12.3 ORAL 97
13 NORTH AMERICA BREAST CANCER DRUGS MARKET, BY END USER 98
13.1 OVERVIEW 99
13.2 HOSPITALS 102
13.3 CANCER CENTERS 102
13.4 SPECIALTY CLINICS 103
13.5 OTHERS 103
?
14 NORTH AMERICA BREAST CANCER DRUGS MARKET, BY DISTRIBUTION CHANNEL 104
14.1 OVERVIEW 105
14.2 HOSPITAL PHARMACY 108
14.3 RETAIL PHARMACY 108
14.4 ONLINE PHARMACY 108
15 NORTH AMERICA BREAST CANCER DRUGS MARKET, BY REGION 110
15.1 OVERVIEW 111
15.2 NORTH AMERICA 115
15.2.1 U.S. 120
15.2.2 CANADA 125
15.2.3 MEXICO 130
16 NORTH AMERICA BREAST CANCER DRUGS MARKET: COMPANY LANDSCAPE 135
16.1 COMPANY SHARE ANALYSIS: NORTH AMERICA 135
17 SWOT ANALYSIS 136
18 COMPANY PROFILES 137
18.1 F. HOFFMANN-LA ROCHE LTD 137
18.1.1 COMPANY SNAPSHOT 137
18.1.2 REVENUE ANALYSIS 137
18.1.3 COMAPANY SHARE ANALYSIS 138
18.1.4 PRODUCT PORTFOLIO 138
18.1.5 RECENT DEVELOPMENTS 139
18.2 PFIZER INC. 141
18.2.1 COMPANY SNAPSHOT 141
18.2.2 REVENUE ANALYSIS 141
18.2.3 COMAPANY SHARE ANALYSIS 142
18.2.4 PRODUCT PORTFOLIO 142
18.2.5 RECENT DEVELOPMENTS 143
18.3 ASTRAZENECA 144
18.3.1 COMPANY SNAPSHOT 144
18.3.2 REVENUE ANALYSIS 144
18.3.3 COMAPANY SHARE ANALYSIS 145
18.3.4 PRODUCT PORTFOLIO 145
18.3.5 RECENT DEVELOPMENT 146
?
18.4 NOVARTIS AG 147
18.4.1 COMPANY SNAPSHOT 147
18.4.2 REVENUE ANALYSIS 147
18.4.3 COMAPANY SHARE ANALYSIS 148
18.4.4 PRODUCT PORTFOLIO 148
18.4.5 RECENT DEVELOPMENT 149
18.5 ELI LILLY AND COMPANY 150
18.5.1 COMPANY SNAPSHOT 150
18.5.2 REVENUE ANALYSIS 151
18.5.3 COMAPANY SHARE ANALYSIS 151
18.5.4 PRODUCT PORTFOLIO 152
18.5.5 RECENT DEVELOPMENTS 152
18.6 ABBVIE, INC. 153
18.6.1 COMPANY SNAPSHOT 153
18.6.2 REVENUE ANALYSIS 153
18.6.3 PRODUCT PORTFOLIO 154
18.6.4 RECENT DEVELOPMENT 154
18.7 BRISTOL-MYERS SQUIBB COMPANY 155
18.7.1 COMPANY SNAPSHOT 155
18.7.2 REVENUE ANALYSIS 155
18.7.3 PRODUCT PORTFOLIO 156
18.7.4 RECENT DEVELOPMENT 156
18.8 EISAI CO., LTD 157
18.8.1 COMPANY SNAPSHOT 157
18.8.2 REVENUE ANALYSIS 157
18.8.3 PRODUCT PORTFOLIO 158
18.8.4 RECENT DEVELOPMENT 158
18.9 KYOWA KIRIN CO., LTD 159
18.9.1 COMPANY SNAPSHOT 159
18.9.2 REVENUE ANALYSIS 159
18.9.3 PRODUCT PORTFOLIO 160
18.9.4 RECENT DEVELOPMENT 160
18.10 MERCK & CO., INC. 161
18.10.1 COMPANY SNAPSHOT 161
18.10.2 REVENUE ANALYSIS 161
18.10.3 PRODUCT PORTFOLIO 162
18.10.4 RECENT DEVELOPMENT 162
?
18.11 MACROGENICS, INC. 163
18.11.1 COMPANY SNAPSHOT 163
18.11.2 REVENUE ANALYSIS 163
18.11.3 PRODUCT PORTFOLIO 164
18.11.4 RECENT DEVELOPMENT 164
18.12 SANOFI 165
18.12.1 COMPANY SNAPSHOT 165
18.12.2 REVENUE ANALYSIS 165
18.12.3 PRODUCT PORTFOLIO 166
18.12.4 RECENT DEVELOPMENTS 166
18.13 TEVA PHARMACEUTICAL INDUSTRIES LTD 167
18.13.1 COMPANY SNAPSHOT 167
18.13.2 REVENUE ANALYSIS 167
18.13.3 PRODUCT PORTFOLIO 168
18.13.4 RECENT DEVELOPMENT 168
18.14 VIATRIS INC 169
18.14.1 COMPANY SNAPSHOT 169
18.14.2 REVENUE ANALYSIS 169
18.14.3 PRODUCT PORTFOLIO 170
18.14.4 RECENT DEVELOPMENT 170
18.15 GILEAD SCIENCES, INC 171
18.15.1 COMPANY SNAPSHOT 171
18.15.2 REVENUE ANALYSIS 171
18.15.3 PRODUCT PORTFOLIO 172
18.15.4 RECENT DEVELOPMENT 172
18.16 TAKEDA PHARMACEUTICAL COMPANY LIMITED 173
18.16.1 COMPANY SNAPSHOT 173
18.16.2 REVENUE ANALYSIS 173
18.16.3 PRODUCT PORTFOLIO 174
18.16.4 RECENT DEVELOPMENT 174
19 QUESTIONNAIRE 175
20 RELATED REPORTS 179

Not Sure / Need Reassuring
- Confirm Content
  - Content is provided by our partners and every effort is made to make Market Report details as clear as possible. If you are not sure the exact content you require is included in this study you can Contact us to double check. To do this you can:
    
    Use the ‘? ASK A QUESTION’ below the license / prices and to the right of this box. This will come directly to our team who will work on dealing with your request as soon as possible.
    
    Write to directly on support@scotts-international.com with details. Please include as much information as possible including the name of report or link so our staff will be able to work on you request.
    
    Telephone us directly on 0048 603 394 346 and an experienced member of team will be on hand to answer.
- Sample Pages
  - With the vast majority of our partners we can obtain Sample Pages to support your decision. This is something we can arrange without revealing your personal details.
    
    It is important to note that we will not be able to provide you the exact data or statistics such as Market Size and Forecasts. Sample pages usually confirm the layout or the Categories included in Charts and Graphs, excluding specific data.
    
    To ask for Sample Pages by contact us through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
- Check for Alternatives
  - Whilst we try to make our online platform as easy to use as possible there is always the possibility that a better alternative has not been found in your search.
    
    To avoid this possibility Contact us through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346 and a Senior Team Member can review your requirements and send a list of possibilities with opinions and recommendations.
Prices / Formats / Delivery
- Prices
  - All prices are set by our partners and should be exactly the same as those listed on their own websites. We work on a Revenue share basis ensuring that you never pay more than what is offered elsewhere.
    
    Should you find the price cheaper on another platform we recommend you to Contact us as we should be able to match this price. You can Contact us though through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
- Discounts
  - As we work in close partnership with our Partners from time to time we can secure discounts and assist with negotiations, this is part of our personalised service to you.
    
    Discounts can sometimes be arranged for speedily placed orders; multiple report purchases or Higher License purchases.
    
    To check if a Discount is possible please Contact our experienced team through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
- Available Currencies
  - Most Market Reports on our platform are listed in USD or EURO based on the wishes of our Partners. To avoid currency fluctuations and potential price differentiations we do not offer the possibility to change the currency online.
    
    Should you wish to pay in a different currency to that advertised online we do accept payments in USD, EURO, GBP and PLN. The price will be calculated based on the relevant exchange rate taken from our National Bank.
    
    To pay in a different above currency to that advertised online please Contact our team and a quotation will be sent within a couple of hours with payment details.
- Licenses
  - License options vary from Partner to Partner as is usually based on the number of Users that will benefitting from the report. It is very important that License ordered is not breached as this could have potential negative consequences for you individually or your employer.
    
    If you have questions or need confirmation about the specific license we recommend you to Contact us and a detailed explanation will be provided.
- Global Site License
  - The Global Site License is the most comprehensive license available. By selecting this license, the Market Report can be shared with other ‘Allowed Users’ and any other member of staff from the same organisation regardless of geographic location.
    
    It is important to note that this may exclude Parent Companies or Subsidiaries.
    
    If you have questions or need confirmation about the specific license we recommend you to Contact us and a detailed explanation will be provided.
- Formats
  - The most common format is PDF, however in certain circumstances data may be present in Excel format or Online, especially in the case of Database or Directories. In addition, for certain higher license options a CD may also be provided.
    
    If you have questions or need clarification about the specific formats we recommend you to Contact us and a detailed explanation will be provided.
- Delivery
  - Delivery is fulfilled by our partners directly. Once an order has been placed we inform the partner by sharing the delivery email details given in the order process.
    
    Delivery is usually made within 24 hours of an order being placed, however it may take longer should your order be placed prior to the weekend or if otherwise specified on the Market Report details page. Additionally, if details have been not fully completed in the Order process a delay in delivery is possible.
    
    If a delay in delivery is expected you will be informed about it immediately.
- Shipping Charges
  - As most Market Reports are delivered in PDF format we almost never have to add additional Shipping Charges. If, however you are ordering a Higher License service or a specific delivery format (e.g. CD version) charges may apply.
    
    If you are concerned about additional Shipping Charges we recommend you to Contact us to double check.
Ordering
- By Credit Card
  - We work in Partnership with PayU to ensure payments are made securely in a fast and effortless way. PayU is the e-payments division of Naspers.
    
    Naspers operates in over 133 International Markets and ranks 3rd Globally in terms of the number of e-commerce customers served.
    
    For more information on PayU please visit: https://www.payu.pl/en/about-us
- By Money Transfer
  - If you require an invoice prior to payment, this is possible. To ensure a speedy delivery of the Market Report we require all relevant company details and you agree to maximum payment terms of 30 days from receipt of order.
    
    With our regular clients deliver of the Market Report can be made prior to receiving payment, however in some circumstances we may ask for payment to be received before arranging for the Market Report to be delivered.
Security
- Website security
  - We have specifically partnered with leading International companies to protect your privacy by using different technologies and processes to ensure security.
    
    Everything submitted to Scotts International is encrypted via SSL (Secure Socket Layer) and all personal information provided to Scotts International is stored on computer systems with limited access in controlled environments.
- Credit Card Security
  - We partner with PayU (https://www.payu.pl/en/about-us) to ensure all credit card payments are made securely in a fast and effortless way.
    
    PayU offers 250+ various payment channels and eWallet services across 4 continents allowing buyers to pay electronically, whether on a computer or a mobile device.